Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06646640 · ClinicalTrials.gov registry record
Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy
A clinical trial of Hemoglobin Disorder, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT06646640 is a study of Hemoglobin Disorder that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06646640, a study of Hemoglobin Disorder, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, longitudinal, non-therapeutic study which includes routine assessment for long-term effects, as per FDA guidelines after receipt of an allogeneic HCT or autologous genetically modified cellular products for hemoglobin disorders. Primary objective: \- To provide long term follow up, for individuals with hemoglobin disorders undergoing allogeneic hematopoietic stem cell transplantation (HCT) or receipt of an autologous genetically modified cellular product to treat their hemoglobinopathy. For individuals receiving a genetically modified cellular product, this long term follow up study is in accordance with the guidelines provided by the Food and Drug Administration (FDA).
Conditions Studied
Study Locations (1)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-06-26 |
| Est. Completion | 2050-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06646640
The ClinicalTrials.gov registry entry for NCT06646640 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemoglobin Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT06646640 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT06646640 about?
NCT06646640 is a clinical study titled "Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy". This is a prospective, longitudinal, non-therapeutic study which includes routine assessment for long-term effects, as per FDA guidelines after receipt of an allogeneic HCT or autologous genetically modified cellular products for hemoglobin disorders. Primary objective: \- To provide long term fol...
What is the current status of trial NCT06646640?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-06-26. Estimated completion is 2050-01.
What conditions does trial NCT06646640 study?
This clinical trial studies the following conditions: Hemoglobin Disorder.
Who is sponsoring clinical trial NCT06646640?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06646640 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.